Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

CMC Biologics was selected by Edimer for their lead product due to its depth of expertise in protein development, analytical development and its cGMP manufacturing capabilities.

Neil Kirby, Ph.D., Edimer CEO, commented, "CMC's extensive experience in the GMP manufacture of therapeutic proteins makes them an ideal company to help us move this product forward. We believe that this product has the potential for making a difference in individuals' lives that currently have no available therapeutic options."

Gustavo Mahler, Ph.D., CMC Biologics Chief Operating Officer noted, "CMC is delighted to be able to assist Edimer in the development and production of this orphan protein. Our two teams are working together in an open and collaborative manner and we are excited about the project's potential."